PharmaCyte Biotech (PMCB) Year-over-year earnings per share growth for the last twelve months

PMCB (pharmacyte.com) - company brandmark

PharmaCyte Biotech (PMCB) is exposed to risks stemming from global biomaterial supply chain disruptions and sanction restrictions. The quarterly earnings per share (EPS) growth rate demonstrates business resilience, with the metric reaching 56.20. Growth is driven by partnerships with oncology centers for cell encapsulation, while operations in the US provide stability and protection under humanitarian law.

pharmacyte.com (PMCB) - Quarterly EPS earnings growth from 07/04/2022 to 11/11/2026

PharmaCyte Biotech (PMCB) - metric breakdowns and financial figures

- market value and analyst target forecast:
Price Chart pharmacyte.com|PMCB - Average Forecast Price
- market capitalization details:
Market Value PharmaCyte|PMCB - Real Price to Acquire Entire Company
- book capitalization data:
Book Value per Share PharmaCyte Biotech|PMCB - Book Capitalization|Market Capitalization to Book Value Ratio pharmacyte.com|PMCB - Cumulative Company Assets
- debt and liquidity details:
Total Debt to Capital PharmaCyte Biotech|PMCB - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity pharmacyte.com|PMCB - Company Aggregate Indebtedness|Debts to Book Capitalization PharmaCyte|PMCB - Company Long-Term Loans and Borrowings|Company Short-Term Debts PharmaCyte Biotech|Quick Liquidity pharmacyte.com
- earnings and valuation multiples indicators:
PMCB - Final Profit|Expected Profit PharmaCyte Biotech|PMCB - Price to Earnings Ratio|Forward P/E Multiple pharmacyte.com|PMCB - PEG Multiple|EV/EBITDA Multiple PharmaCyte|PMCB - Operating profit before deduction of amortization|Net earnings per share for the last 12 months PharmaCyte Biotech|PMCB - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months pharmacyte.com|PMCB - Net earnings per one share growth for the current year|Earnings growth forecast for next year PharmaCyte Biotech
General company analysis:PharmaCyte Biotech Inc. - PMCB
Flagship merchandise of pharmacyte.com

Investors must evaluate the fundamental quality and resilience of PharmaCyte Biotech (PMCB) through the dynamics of quarterly earnings per share. By analyzing the growth rate of quarterly EPS, one can identify hidden imbalances and stagnation risks, which for PharmaCyte Biotech (PMCB) depend directly on the reliability of external CMO contractors providing critical encapsulation processes and clinical trials.

Who PharmaCyte Biotech competes with

TriSalus Life Sciences, Inc. (TLSI) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months RenovoRx Inc (RNXT)